JP2024508597A5 - - Google Patents
Info
- Publication number
- JP2024508597A5 JP2024508597A5 JP2023541591A JP2023541591A JP2024508597A5 JP 2024508597 A5 JP2024508597 A5 JP 2024508597A5 JP 2023541591 A JP2023541591 A JP 2023541591A JP 2023541591 A JP2023541591 A JP 2023541591A JP 2024508597 A5 JP2024508597 A5 JP 2024508597A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr
- sequence
- sequence seq
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110255430.8 | 2021-03-09 | ||
| CN202110255430 | 2021-03-09 | ||
| PCT/CN2022/078327 WO2022188652A1 (zh) | 2021-03-09 | 2022-02-28 | Ror1结合蛋白及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024508597A JP2024508597A (ja) | 2024-02-28 |
| JP2024508597A5 true JP2024508597A5 (https=) | 2025-03-06 |
Family
ID=83226356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541591A Pending JP2024508597A (ja) | 2021-03-09 | 2022-02-28 | Ｒｏｒ１結合タンパク質及びその用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240018237A1 (https=) |
| EP (1) | EP4306540A4 (https=) |
| JP (1) | JP2024508597A (https=) |
| KR (1) | KR20230156021A (https=) |
| CN (1) | CN116829599A (https=) |
| CA (1) | CA3207635A1 (https=) |
| MX (1) | MX2023008176A (https=) |
| WO (1) | WO2022188652A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| ES2657970T3 (es) * | 2010-12-01 | 2018-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anticuerpos contra ROR1 de conejo/ser humano quiméricos |
| EP3604339B1 (en) | 2011-01-14 | 2021-03-10 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| KR102236367B1 (ko) | 2013-07-26 | 2021-04-05 | 삼성전자주식회사 | DARPin을 포함하는 이중 특이 키메라 단백질 |
| CA2942546C (en) | 2014-03-17 | 2022-11-22 | Mitsubishi Tanabe Pharma Corporation | Antibody-fynomer conjugates |
| CN105924533B (zh) * | 2016-07-13 | 2020-04-21 | 北京康爱瑞浩生物科技股份有限公司 | Ror1特异性嵌合抗原受体及其应用 |
| AU2018289581C1 (en) * | 2017-06-23 | 2025-01-30 | VelosBio Inc. | ROR1 antibody immunoconjugates |
| CN109836498A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种靶向ror1的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| GB201721802D0 (en) * | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| CN108441505B (zh) * | 2018-05-28 | 2023-07-07 | 上海恒润达生生物科技股份有限公司 | 一种靶向ror1的嵌合抗原受体及其用途 |
| CA3105816A1 (en) * | 2018-07-10 | 2020-01-16 | Precigen, Inc. | Ror-1 specific chimeric antigen receptors and uses thereof |
| SG11202107976SA (en) * | 2019-01-29 | 2021-08-30 | Juno Therapeutics Inc | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
-
2022
- 2022-02-28 WO PCT/CN2022/078327 patent/WO2022188652A1/zh not_active Ceased
- 2022-02-28 KR KR1020237024374A patent/KR20230156021A/ko active Pending
- 2022-02-28 EP EP22766178.2A patent/EP4306540A4/en active Pending
- 2022-02-28 MX MX2023008176A patent/MX2023008176A/es unknown
- 2022-02-28 US US18/260,556 patent/US20240018237A1/en active Pending
- 2022-02-28 JP JP2023541591A patent/JP2024508597A/ja active Pending
- 2022-02-28 CA CA3207635A patent/CA3207635A1/en active Pending
- 2022-02-28 CN CN202280009364.9A patent/CN116829599A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7562528B2 (ja) | 抗体及びその用途 | |
| JP2024125370A (ja) | クローディン１８．２結合部分およびその利用 | |
| CN110431231B (zh) | 抗-cd3抗体和包含所述抗体的分子 | |
| Chen et al. | A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy | |
| JP7843824B2 (ja) | 抗体および使用方法 | |
| WO2021063201A1 (zh) | 抗pd-1抗体及其用途 | |
| WO2019022187A1 (ja) | 抗ｃｄ１４７抗体 | |
| WO2023040945A1 (zh) | 特异性结合pd-1的蛋白及其医药用途 | |
| WO2012020059A1 (en) | Humanized egfr antibodies | |
| WO2023040940A1 (zh) | Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症 | |
| CN113574069A (zh) | 抗pd-l1抗体及其用途 | |
| JP2025511288A (ja) | 抗ｐｖｒｉｇ抗体、その医薬組成物及びその使用 | |
| WO2022240833A1 (en) | Alpha 5 beta 1 integrin binding agents and uses thereof | |
| JP2026027248A (ja) | 抗原結合分子およびその使用 | |
| JP2024508597A5 (https=) | ||
| JP2025525408A (ja) | 二重特異性抗体及びその応用 | |
| JP2025537255A (ja) | 抗アルファ５インテグリン抗体及びその使用 | |
| WO2023221935A1 (zh) | 结合pd-l1和cldn18.2的抗体及其用途 | |
| JP2024508597A (ja) | Ｒｏｒ１結合タンパク質及びその用途 | |
| JP2020508694A5 (https=) | ||
| JP2020508694A (ja) | ＥｒｂＢ２抗体およびその使用 | |
| WO2021178253A1 (en) | Anti-cd19 antibodies and methods of using and making thereof | |
| JPWO2016163433A1 (ja) | 抗ｆｇｆｒ２抗体と他剤を含む組成物 | |
| US20240301062A1 (en) | Anti-cd3 multispecific antibodies and methods of use | |
| WO2026009973A1 (ja) | 抗変異ｃａｌｒ抗体を含む組成物および抗体の作製方法 |